Is G a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Advanced Technology Solutions mix shift, with revenue (ttm) at ~$5.25B. The bear case rests on the central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base. Analysts covering it are spread from $31.00 to $58.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $31.00, -8.4% from the $33.86 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Advanced Technology Solutions mix shift. ATS reached roughly ~$363 million in Q2 2026, up more than ~24% year over year, and is guided to grow at least ~25% for the full year. The most optimistic analyst target on G is $58.00, +71.3% from the $33.86 price. That figure is only reachable if this thesis works close to its best case.

The central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base. A second risk is client concentration and long sales cycles, where a handful of large renewals repriced downward can move a quarter. Currency is a live factor because costs sit largely in Indian rupees and Philippine pesos while revenue is billed mostly in dollars, so moves cut both ways on margin. Immigration and offshoring policy, along with any US tax or visa change targeting outsourced services, is a recurring political exposure for the whole India-delivery cohort. Finally, the cheap multiple is itself information: the market is pricing a business it believes is being disintermediated, and a low valuation offers no protection if that view turns out to be correct. The most pessimistic published target is $31.00, -8.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Business-process and analytics services firm spun out of GE in 2005, running finance, supply-chain and risk operations and repositioning around agentic AI.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Advanced Technology Solutions mix shift) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is that agentic AI compresses the price of the work Genpact performs faster than volumes or new offerings replace it, and analysts have flagged exactly this: ATS may not fully offset a slowing legacy base) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It runs business processes for large companies under multi-year contracts: accounts payable and receivable, procurement, financial planning, insurance claims, anti-money-laundering alert review, supply-chain planning and customer service. It also provides data, analytics and AI implementation work. Clients outsource these functions to cut cost and to access specialist process expertise they do not want to build internally.

Genpact Limited trades on the New York Stock Exchange under the ticker G, so it is accessible through any standard US brokerage account that supports NYSE-listed shares, including via fractional shares at brokers that offer them. Some investors hold it inside a broader IT-services or thematic grouping alongside peers rather than as a standalone position.

Yes. Q2 2026 produced net revenue of roughly ~$1.34 billion with gross margin near ~36.5% and adjusted diluted EPS of about ~$1.00, up ~13.6% year over year. The company has been consistently profitable and cash-generative for years, which is what funds the dividend and the buyback programme.